Navigation Links
XTENT to Retain Investment Bank to Pursue Strategic Alternatives
Date:1/23/2009

d Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's ability to reduce its costs or the timing of such reductions, XTENT's ability to maximize the value of its assets or the timing thereof, XTENT's ability to engage suitable advisors, XTENT's ABILITY TO SUCCESSFULLY IMPLEMENT A STRATEGIC ALTERNATIVE, THE DECISION BY XTENT TO EXPLORE ONE OR MORE STRATEGIC ALTERNATIVES, WHETHER THE STRATEGIC ALTERNATIVES COULD RESULT IN MAXIMIZING SHAREHOLDER VALUE, WHETHER THE ENGAGEMENT OF ADVISORS WILL RESULT IN A STRATEGIC ALTERNATIVE PURSUED OR EFFECTED BY XTENT, AND OTHER RISKS. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's most recent quarterly report on Form 10-Q for the quarter ended September 30, 2008. This quarterly report was filed with the SEC on November 12, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update public
'/>"/>

SOURCE XTENT
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
2. National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC
3. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
4. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
5. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
6. Dragon retains leading investor relations firm
7. Interleukin Genetics Retains Top Life Science Communications Firms
8. SPO Medical Retains American Capital Ventures for Investor Relations Services
9. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
10. CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
11. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... LANSING, Mich. , July 7, 2015  Neogen ... has signed an agreement to expand its relationship with ... sequencing and genomics. Under the agreement, Illumina will market ... on Illumina Infinium ® BeadArray technology, to the ... Illumina,s largest agrigenomic customers through its GeneSeek ® ...
(Date:7/7/2015)... , July 7, 2015   Moleculera ... two-year, $300,000 matching grant from the Oklahoma Center ... This grant supports the development and clinical validation ... directed against neuronal antigens in patients experiencing neuropsychiatric ... Such panels are intended to assist physicians in ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... from $107.56 million in 2015, growing at a CAGR of 17.89% between 2015 ... RNA-based aptamers, and XNA-based aptamers. Based on applications, the report is segmented into ...
(Date:7/7/2015)... ... ... CSM, a leading clinical trial supply company, today announced that Michael Morse ... background in financial management and accounting, bringing over 20 years of experience in the ... oversee all financial areas of the company to both strengthen CSM’s financial strategy and ...
Breaking Biology Technology:Neogen signs commercialization agreement with Illumina 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5CSM Appoints Michael Morse as Vice President of Finance 2
... , , SAN ... ) is scheduled to present at the Canaccord Adams 29th Annual ... 13, 2009, 2:00 p.m. Eastern Time. , , ... webcasts of these presentations will be accessible on the Company,s website ...
... MINNEAPOLIS, Aug. 4 Techne Corporation (Nasdaq: TECH ) ... of $0.25 per share for the quarter ended June 30, 2009. ... shareholders of record on August 17, 2009. Future cash dividends will ... , Techne Corporation has two operating subsidiaries: Research ...
... , PRINCETON, N.J., Aug. 4 ... the Company), a late-stage biopharmaceutical company, announced today that ... States Food and Drug Administration (FDA) has granted Orphan ... for the treatment of gastrointestinal symptoms associated with chronic ...
Cached Biology Technology:Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 3DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 4DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 5DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 6
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... -- The companion diagnostics market has experienced significant growth ... most promising areas within the IVD market. A myriad ... highly attractive market of companion diagnostics, many of them ... explosive M&A trend in the companion diagnostics market is ...
... 9.5 billion people by 2050, humanity faces the challenge of ... amounts of water, fertilizer and arable land as today. ... needs by discovering a gene that could lead to new ... The gene, called Scarecrow, is the first discovered to control ...
... as they race to cover and ultimately heal wounds to ... a mystery today. Researchers once thought only the cells ... were actively moving while dividing cells passively filled in the ... physicist Herbert Levine and his colleagues have discovered that the ...
Cached Biology News:Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 2Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 3Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 4Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 5Newly discovered 'scarecrow' gene might trigger big boost in food production 2Cells 'flock' to heal wounds 2Cells 'flock' to heal wounds 3
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
KOR-1 (C-20)...
KV beta.1 (Q-13)...
Biology Products: